Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 2/20 | 0.47 |
| ▸ | HSD17B1 | P14061 | 2/20 | 0.45 |
| ▸ | HSD17B2 | P37059 | 2/20 | 0.45 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | MGAM | O43451 | 1/20 | 0.41 |
| ▸ | SI | P14410 | 1/20 | 0.41 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.41 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.40 |
| ▸ | USP7 | Q93009 | 2/20 | 0.40 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.39 |
| ▸ | CDK2 | P24941 | 1/20 | 0.39 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 3/20 | 0.39 |
| ▸ | RAB9A | P51151 | 3/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | STAT3 | P40763 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | ESR1 | P03372 | 3/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10141022 | 0.84 | CYP11B1 (0.48) | CYP11B1GAACYP11B2CCNE1CDK2 | |
| SCHEMBL26759340 | 0.82 | XDH (0.44) | CYP11B1CYP11B2CCNE1CDK2CDK5 | |
| SCHEMBL19272859 | 0.82 | SMN1; SMN2 (0.47) | CYP11B1GAAMGAMSIMGAM2 | |
| SCHEMBL26759020 | 0.82 | PTPN11 (0.40) | CYP11B1CYP11B2CCNE1CDK2CDK5 | |
| SCHEMBL26759056 | 0.82 | HDAC1 (0.41) | CYP11B1GAACYP11B2CDK2NPC1 | |
| SCHEMBL153089 | 0.81 | CYP11B1 (0.56) | CYP11B1CYP11B2CCNE1CDK2CDK5 | |
| SCHEMBL18641409 | 0.81 | CYP11B1 (0.47) | CYP11B1HSD17B1HSD17B2GAAMGAM | |
| SCHEMBL6662146 | 0.81 | RAB9A (0.56) | CYP11B1HSD17B1HSD17B2GAACCNE1 | |
| SCHEMBL8542095 | 0.81 | RAB9A (0.56) | CYP11B1HSD17B1HSD17B2GAACCNE1 | |
| Hydrochloric Acid SCHEMBL18641417 | 0.81 | CYP11B1 (0.46) | CYP11B1HSD17B1HSD17B2GAAMGAM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080275046-A1 | Compounds Comprising an Oxazole or Thiazole Moiety, Processes for Making Them, and Their Uses | UCB PHARMA, S.A. (BE) | 2008-11-06 | — | — | US | claimed |
| EP-1866293-A1 | COMPOUNDS COMPRISING AN OXAZOLE OR THIAZOLE MOIETY, PROCESSES FOR MAKING THEM, AND THEIR USES | UCB Pharma, S.A. (BE) | 2007-12-19 | — | — | EP | claimed |
| WO-2006103045-A1 | COMPOUNDS COMPRISING AN OXAZOLE OR THIAZOLE MOIETY, PROCESSES FOR MAKING THEM, AND THEIR USES | UCB PHARMA S.A. (BE) | 2006-10-05 | — | — | WO | claimed |
| US-20240025890-A1 | HEPATITIS B CORE PROTEIN MODULATORS | ASSEMBLY BIOSCIENCES INC (US) | 2024-01-25 | — | — | US | disclosed |
| US-11814376-B2 | Hepatitis b core protein modulators | ASSEMBLY BIOSCIENCES, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| US-7790720-B2 | Compounds comprising an oxazole or thiazole moiety, processes for making them, and their uses | UCB PHARMA, S.A. (BE) | 2010-09-07 | — | — | US | disclosed |
| US-20080275046-A1 | Compounds Comprising an Oxazole or Thiazole Moiety, Processes for Making Them, and Their Uses | UCB PHARMA, S.A. (BE) | 2008-11-06 | — | — | US | disclosed |
| EP-1866293-A1 | COMPOUNDS COMPRISING AN OXAZOLE OR THIAZOLE MOIETY, PROCESSES FOR MAKING THEM, AND THEIR USES | UCB Pharma, S.A. (BE) | 2007-12-19 | — | — | EP | disclosed |
| WO-2006103045-A1 | COMPOUNDS COMPRISING AN OXAZOLE OR THIAZOLE MOIETY, PROCESSES FOR MAKING THEM, AND THEIR USES | UCB PHARMA S.A. (BE) | 2006-10-05 | — | — | WO | disclosed |
| CN-1037268-C | Antipicornaviral pyridazinamines | JANSSEM PHARMACEUTICA N V (BE) | 1998-02-04 | — | — | CN | disclosed |
| EP-0435381-B1 | Antipicornaviral pyridazinamines | JANSSEN PHARMACEUTICA NV (BE) | 1995-11-02 | — | — | EP | disclosed |
| US-5196535-A | Viricides | JANSSEN PHARMACEUTICA N.V. (BE) | 1993-03-23 | — | — | US | disclosed |
| US-5100893-A | Viricides, effective against picorna virus, durability | JANSSEN PHARMACEUTICA N.V. (BE) | 1992-03-31 | — | — | US | disclosed |
| CN-1052857-A | The preparation method of the pyridazine amine that antipicornaviral is used | JANSSEN PHARMACEUTICA NV (BE) | 1991-07-10 | — | — | CN | disclosed |
| EP-0435381-A1 | Antipicornaviral pyridazinamines | JANSSEN PHARMACEUTICA N.V. (BE) | 1991-07-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240025890-A1 | HEPATITIS B CORE PROTEIN MODULATORS | HAVCR2, FABP1, MAVS | CYP11B1 3005/4885HSD17B1 3591/4885HSD17B2 3671/4885 |
| US-11814376-B2 | Hepatitis b core protein modulators | HAVCR2, FABP1, MAVS | CYP11B1 3005/4885HSD17B1 3591/4885HSD17B2 3671/4885 |
| US-20080275046-A1 | Compounds Comprising an Oxazole or Thiazole Moiety, Processes for Making Them, and Their Uses | OXER1, OXTR, OGFR | CYP11B1 335/4885HSD17B1 640/4885HSD17B2 672/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.